Claims
- 1. A compound of the formula (I):
- 2. The compound according to claim 1 wherein A is direct link or a member selected from the group consisting of:
- 3. The compound according to claim 1 wherein A is a member selected from the group consisting of:
- 4. The compound according to claim 1 wherein A is a member selected from the group consisting of:
- 5. The compound according to claim 1 wherein A is a member selected from the group consisting of:
- 6. A pharmaceutical composition comprising an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- 7. The pharmaceutical composition comprising an effective amount of a compound according to claim 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- 8. The pharmaceutical composition comprising an effective amount of a compound according to claim 3, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- 9. The pharmaceutical composition comprising an effective amount of a compound according to claim 4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- 10. The pharmaceutical composition comprising an effective amount of a compound according to claim 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
- 11. A method of inhibiting adenylyl cyclase in a patient comprising administering a composition according to claim 6 to a patient in need thereof.
- 12. A method of inhibiting adenylyl cyclase in a patient comprising administering a composition according to claim 7 to a patient in need thereof.
- 13. A method of inhibiting adenylyl cyclase in a patient comprising administering a composition according to claim 8 to a patient in need thereof.
- 14. A method of inhibiting adenylyl cyclase in a patient comprising administering a composition according to claim 9 to a patient in need thereof.
- 15. A method of inhibiting adenylyl cyclase in a patient comprising administering a composition according to claim 10 to a patient in need thereof.
- 16. The method according to claim 11, further comprising inhibiting or preventing a patient's fibroproliferative vasculopathy following vascular injury or a vascular surgical operation, wherein said composition is administered to a patient in an effective amount of a compound subsequent to a vascular injury, or subsequent to a vascular surgical operation.
- 17. The method according to claim 16 wherein the composition is administered for one to two weeks after the injury or surgical operation.
- 18. The method according to claim 17 wherein fibroproliferative vasculopathy is selected from the group consisting of chronic allograft rejection, or vascular restenosis following vascular trauma.
- 19. A method of treating congestive heart failure comprising administering an effective amount of a pharmaceutical composition according to claim 6 to a patient in need thereof.
- 20. A method of treating congestive failure comprising administering an effective amount of a pharmaceutical composition according to claim 7 to a patient in need thereof.
- 21. A method of treating congestive failure comprising administering an effective amount of a pharmaceutical composition according to claim 8 to a patient in need thereof.
- 22. A method of treating congestive failure comprising administering an effective amount of a pharmaceutical composition according to claim 9 to a patient in need thereof.
- 23. A method of treating congestive failure comprising administering an effective amount of a pharmaceutical composition according to claim 10 to a patient in need thereof.
RELATED APPLICATION
[0001] This application claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Application Serial No. 60/249,465 filed on Nov. 20, 2000, which is herein incorporated in its entirety by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60249465 |
Nov 2000 |
US |